Vermilion Research - Select Sector SPDR-Health Care (XLV) Vermilion ETF Pathfinder: Actionable ETF research Ideas

Report

Vermilion Research

Dave Nicoski ...

Ross LaDuke

EUR 45.89 For Business Accounts Only

Vermilion ETF Pathfinder: Actionable ETF research & Ideas

Downgrading Health Care to Underweight

Our outlook remains bullish following the S&P 500's multi-month base breakout above 5670-5783, alongside constructive market dynamics. The path of least resistance is higher. We have discussed for the past two+ weeks how we would treat any pre-election pullback as a buying opportunity, and we are finally getting a pullback. We expect to see support on the SPX at 5655-5670, and we will remain bullish as long as 5655 support holds.

Downgrading Health Care to Underweight. We are downgrading Health Care to underweight; RS on the cap-weighted XLV is breaking to YTD lows – reduce exposure/be selective. We view new RS lows on the XLV (a defensive Sector) as yet another risk-on signal that helps support our bullish outlook

04/11/2024 1 EN

Underlying

Select Sector SPDR-Health Care

See profile

US81369Y2090 NYSE Arca United States

Provider

Vermilion Research

Vermilion Research delivers timely, actionable, and unique research inputs to professional investors. Our research strategists highlight securities which we believe are at major inflection points, based on our various proprietary technical indicators, and offer asymmetric risk/return profiles. We believe our research methodology, which is not limited by industry sector or market capitalization, enables us to deliver superior investment recommendations.

Our process begins by organizing all actively traded stocks into coherent sectors, then into logical industry groups. We then apply our proprietary relative strength tools to identify developing price trends. Once attractive trends are identified within a selected sectors or groups, we screen for individual stocks which we believe offer the best risk/reward profile. Vermilion offers U.S. and global equity market research products. Vermilion’s research team, which has received numerous awards and accolades, has a combined 70 year of experience in the analysis of investment securities.

See profile

Analysts

Dave Nicoski

Ross LaDuke

Other Reports on these Companies

Vermilion Research

Vermilion ETF Pathfinder: Actionable ETF research & Ideas

Considering constructive market dynamics and the recent SPX breakout above 5783 following several months of consolidation, we are upgrading our outlook to bullish. Since late-July, our outlook has been neutral on the S&P 500 (SPX), preferring to buy near 5100-5200 support and sell near 5670-5783 resistance until there is a break in either direction. The market is breaking to new highs, hence our upgrade. We would treat any pre-election pullback as a buying opportunity, as long as the SPX holds above 5670. Downgrading Real Estate, Staples, and Health Care to Market Weight. We are downgrading R...

EUR 45.89

October 21, 2024 October 21, 2024 1 EN

Vermilion Research

Vermilion ETF Pathfinder: Actionable ETF research & Ideas

Upgrading Real Estate, Staples, and Health Care The S&P 500 (SPX) is back to test YTD highs and important resistance in the 5670-5783 range. This is an important target/resistance area we have discussed for over a month; using the 2007 SPX topping analog which has tracked the current market almost perfectly, it would suggest a 2% or less move above the prior all-time high set in July at 5670 before topping, which is where we get the 5783 number. As long as the SPX does not have a weekly close above 5783 we continue to recommend reducing risk and shifting to defensives, and this is the ideal t...

EUR 45.89

September 23, 2024 September 23, 2024 1 EN

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

EUR 45.89

11h / 3m 11h / 3m 1 EN

Dave Nicoski ... (+2)

Dave Nicoski
Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Downgrading Health Care to Underweight Our outlook remains bullish following the S&P 500's multi-month base breakout above 5670-5783, alongside constructive market dynamics. The market is quite clearly telling us that the path of least resistance is higher. We would treat any pre-election pullback (if it comes) as a buying opportunity, and we expect to see support on the SPX at 5760 and 5655-5670. The prior two election years (2016 and 2020) saw 5% and 10% pullbacks, respectfully, during September/October; this year's 10% pullback came a bit earlier (in July/August), and leads us to believe a...

EUR 45.89

October 29, 2024 October 29, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Vermilion ETF Pathfinder: Actionable ETF research & Ideas

Vermilion ETF Pathfinder: Actionable ETF research & Ideas

Vermilion ETF Pathfinder: Actionable ETF research & Ideas

Vital Signs: Actionable charts

Vermilion Compass: Weekly Equity Strategy

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe